NCT07774325
A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood
StatusActive, Not Recruiting
PhasePhase 1
SponsorBoehringer Ingelheim
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later, enrollment reduced 38%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment reduced: 16 → 10 participants
- Primary completion pushed from Oct 6, 2026 to Feb 21, 2027
- Study completion pushed from Oct 26, 2026 to Mar 8, 2027
- Notable Eligibility criteria expanded, about 9 words
- Enrollment closed, study ongoing
- Site details revised
- Notable Recruitment opened
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Timeframe: up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Timeframe: up to 4 days
Secondary (1)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Arms and interventions
Treatment sequence 1Experimental
Sequence: 1. \- Reference treatment (BI 3000202) 2. \- Test treatment 1 (BI 3000202 + Ciclosporin) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)
Treatment sequence 2Experimental
Sequence: 1. \- Test treatment 1 (BI 3000202 + Ciclosporin) 2. \- Reference treatment (BI 3000202) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)
Drugs: BI 3000202, Ciclosporin, Itraconazole
Sites
1 site in 1 country
- Humanpharmakologisches Zentrum BiberachBiberach, Germany